Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.

Studied

A propensity-matched observational cohort compared on-treatment weight loss and gastrointestinal adverse events among adults receiving tirzepatide or semaglutide in routine care.

Who / model

Adults with overweight or obesity were identified from linked US health-record and dispensing data; participants had no prior GLP-1 receptor agonist use.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Tirzepatide use was associated with greater weight loss than semaglutide, while gastrointestinal adverse-event rates were similar.

Limits

This was an observational on-treatment study with substantial treatment discontinuation, so it cannot establish comparative causal effects.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary